Stem cell injection may ward off glaucoma: study

Image
Press Trust of India Washington
Last Updated : Jul 27 2016 | 12:42 PM IST
An infusion of stem cells harvested from a patient's own skin may help restore proper drainage for fluid-clogged eyes at risk of glaucoma, a new study in mice has found.
Researchers led by Markus Kuehn from University of Iowa in the US injected stem cells into the eyes of mice with glaucoma.
The influx of cells regenerated the tiny, delicate patch of tissue known as the trabecular meshwork, which serves as a drain for the eyes to avoid fluid buildup.
When fluid accumulates in the eye, the increase in pressure could lead to glaucoma. The disease damages the optic nerve and can result in blindness.
Researchers found that an infusion of stem cells could help restore proper drainage for fluid-clogged eyes at risk for glaucoma.
"We believe that replacement of damaged or lost trabecular meshwork cells with healthy cells can lead to functional restoration following transplantation into glaucoma eyes," said Kuehn.
One potential advantage of the approach is that the type of stem cells used - called induced pluripotent stem cells - could be created from cells harvested from a patient's own skin.
That gets around the ethical dilemma of using foetal stem cells, and it also lessens the chance of the patient's body rejecting the transplanted cells.
Researchers were able to get the stem cells to grow into cells like those of the trabecular meshwork by culturing them in a solution that had previously been "conditioned" by actual human trabecular meshwork cells.
They saw that the stem cell injection led to a proliferation of new endogenous cells within the trabecular meshwork.
In other words, it appeared the stem cells not only survived on their own, but coaxed the body into making more of its own cells within the eye, thus multiplying the therapeutic effect.
Researchers measured the effects in the mice nine weeks after the transplant. Lab mice generally live only two or three years, and nine weeks is roughly equal to about five or six years for humans.
The findings hold promise for the most common form of glaucoma, known as primary open angle glaucoma, researchers said.
The findings were published in the journal Proceedings of the National Academy of Sciences.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 27 2016 | 12:42 PM IST

Next Story